BACKGROUND: Among hemodialysis (HD) patients, those who have diabetes have poorer cardiovascular outcomes than non-diabetic patients, but the impact of diabetes on cardiovascular outcomes has not been fully elucidated in HD patients undergoing coronary revascularization. METHODS AND RESULTS: We identified 375 HD patients (203 diabetes, 172 non-diabetes) and 9,006 patients without HD (3,455 diabetes, 5,551 non-diabetes) in the database of the CREDO-Kyoto registry of patients undergoing their first coronary revascularization. In non-HD patients, significantly higher risks of death (10.8% vs. 7.7%, P < 0.0001; adjusted hazard ratio (HR) 1.29, P < 0.0001) and major adverse cardiovascular events (MACE), a composite of death, myocardial infarction and stroke (18.8% vs. 13.3%, P < 0.0001; HR 1.36, P < 0.0001) were seen in diabetic patients than in non-diabetic patients through 4-year follow-up. Analysis in HD patients showed that the duration of HD before first coronary revascularization was significantly shorter in diabetic patients than in non-diabetic patients (median interval: 858 vs. 2,216 days, P < 0.0001). In contrast to the results in non-HD patients, the risks of death (41.9% vs. 39.1%, P=0.75; HR 0.98, P=0.93) and MACE (45.6% vs. 45.8%, P=0.83; HR 0.87, P=0.50) after first revascularization were comparable between diabetic and non-diabetic HD patients. There were significant interactions between HD and diabetes for death and for MACE. CONCLUSIONS: HD patients who require coronary revascularization have extremely poor outcomes irrespective of concomitant diabetes.
BACKGROUND: Among hemodialysis (HD) patients, those who have diabetes have poorer cardiovascular outcomes than non-diabeticpatients, but the impact of diabetes on cardiovascular outcomes has not been fully elucidated in HDpatients undergoing coronary revascularization. METHODS AND RESULTS: We identified 375 HDpatients (203 diabetes, 172 non-diabetes) and 9,006 patients without HD (3,455 diabetes, 5,551 non-diabetes) in the database of the CREDO-Kyoto registry of patients undergoing their first coronary revascularization. In non-HDpatients, significantly higher risks of death (10.8% vs. 7.7%, P < 0.0001; adjusted hazard ratio (HR) 1.29, P < 0.0001) and major adverse cardiovascular events (MACE), a composite of death, myocardial infarction and stroke (18.8% vs. 13.3%, P < 0.0001; HR 1.36, P < 0.0001) were seen in diabeticpatients than in non-diabeticpatients through 4-year follow-up. Analysis in HDpatients showed that the duration of HD before first coronary revascularization was significantly shorter in diabeticpatients than in non-diabeticpatients (median interval: 858 vs. 2,216 days, P < 0.0001). In contrast to the results in non-HDpatients, the risks of death (41.9% vs. 39.1%, P=0.75; HR 0.98, P=0.93) and MACE (45.6% vs. 45.8%, P=0.83; HR 0.87, P=0.50) after first revascularization were comparable between diabetic and non-diabetic HDpatients. There were significant interactions between HD and diabetes for death and for MACE. CONCLUSIONS:HDpatients who require coronary revascularization have extremely poor outcomes irrespective of concomitant diabetes.